NEW YORK (GenomeWeb News) – Glycomics firm Ezose Sciences said today it has fully aligned its business with Shionogi's Diagnostics Division following its acquisition by the Japanese pharmaceutical firm.
Ezose also said that Kiyoshi Nagata has been named chairman and CEO of Ezose, which was formed in 2009 as a US joint venture of Shionogi and Sumitomo Bakelite. Nagata replaces John Keller, who continues to serve as a member of Ezose's board, and is president and CEO of Shionogi Inc., the US-based group company of Shionogi.
Nagata is also corporate officer and executive general manager of Shiniogi's Diagnostics Division.
"The alignment of Ezose's biomarker discovery platform with our existing diagnostics and companion diagnostics development and commercialization capabilities provides a unique opportunity for both internal and partnership programs," Nagata said in a statement. "We are bringing the promise of glycomics for biomarkers and personalized medicine into practical use for accelerating drug development and enhancing medical practice."
Ezose, based in Pine Brook, NJ, offers high-throughput glycan analysis services for the discovery of disease biomarkers and therapeutic targets and in support of biologics drug development and manufacture. Its lead technology platform, called GlycanMap, combines bead-based glycan capture technology, automated sample processing, high-throughput MALDI mass spectrometry, and bioinformatics for the high-throughput qualitative and quantitative mapping of glycans, according to the company's website.